Timely course of SARS-CoV-2 infections and vaccinations in patients with hemato-oncological diseases: analysis of a real-life cohort

[1]  T. Choueiri,et al.  Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium , 2023, The Lancet Regional Health - Americas.

[2]  M. Filetti,et al.  Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Max Kozlov.  Should COVID vaccines be given yearly? Proposal divides US scientists , 2023, Nature.

[4]  Siddharth Singh,et al.  Association of COVID-19 Vaccination With Breakthrough Infections and Complications in Patients With Cancer. , 2022, JAMA oncology.

[5]  M. Ciccozzi,et al.  A Lesson from the Green Pass Experience in Italy: A Narrative Review , 2022, Vaccines.

[6]  M. Piccart,et al.  Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study , 2022, The Lancet Oncology.

[7]  Q. Khan,et al.  Risk of SARS-CoV-2 Breakthrough Infection in Vaccinated Cancer Patients: A Retrospective Cohort Study , 2022, Journal of Hematology & Oncology.

[8]  S. Ostrowski,et al.  Patients with CLL have a lower risk of death from COVID-19 in the Omicron era , 2022, Blood.

[9]  N. Berger,et al.  Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US Between December 2020 and November 2021 , 2022, JAMA oncology.

[10]  H. Ullum,et al.  Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study , 2022, The Lancet Infectious Diseases.

[11]  M. Preusser,et al.  Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron , 2022, Cancer Cell.

[12]  U. Topaloglu,et al.  Risk and Outcome of Breakthrough COVID-19 Infections in Vaccinated Patients With Cancer: Real-World Evidence From the National COVID Cohort Collaborative , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  S. Bhatt,et al.  Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study , 2022, The Lancet.

[14]  S. Kalnicki,et al.  Impact of COVID-19 on case fatality rate of patients with cancer during the Omicron wave , 2022, Cancer Cell.

[15]  M. Preusser,et al.  Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events – a retrospective cohort study , 2022, European Journal of Cancer.

[16]  J. Bhiman,et al.  Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa , 2021, medRxiv.

[17]  A. Reiner-Benaim,et al.  Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer , 2021, Annals of Oncology.

[18]  M. Piccart,et al.  Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study , 2021, The Lancet Oncology.

[19]  T. Barrientos-Gutiérrez,et al.  Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis , 2021, European journal of cancer.

[20]  F. Scotté,et al.  Seroconversion rate after vaccination against COVID-19 in patients with cancer—a systematic review , 2021, Annals of Oncology.

[21]  T. Barrientos-Gutiérrez,et al.  Immunogenicity and Risk of SARS-CoV-2 Infection after COVID-19 Vaccination in Patients with Cancer: A Systematic Review and Meta-Analysis , 2021, European Journal of Cancer.

[22]  M. Preusser,et al.  Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations. , 2021, JAMA oncology.

[23]  G. Visani,et al.  Immunological Response Against SARS-COV-2 After BNT162b2 Vaccine Administration Is Impaired in Allogeneic but Not in Autologous Stem Cell Transplant Recipients , 2021, Frontiers in Oncology.

[24]  K. Stiasny,et al.  SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity , 2021, Annals of the Rheumatic Diseases.

[25]  M. Dimopoulos,et al.  Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose , 2021, Blood.

[26]  E. D. de Vries,et al.  The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate , 2021, Annals of Oncology.

[27]  Nguyen H. Tran,et al.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[28]  R. Neher,et al.  Nextclade: clade assignment, mutation calling and quality control for viral genomes , 2021, J. Open Source Softw..

[29]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[30]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[31]  N. Uriel,et al.  COVID-19 in solid organ transplant recipients: Initial report from the US epicenter , 2020, American Journal of Transplantation.

[32]  R. Gale,et al.  COVID-19 in persons with haematological cancers , 2020, Leukemia.

[33]  F. M. Stewart,et al.  Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[34]  Ting Yu,et al.  Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study , 2020, The Lancet Respiratory Medicine.

[35]  Ruchong Chen,et al.  Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China , 2020, The Lancet Oncology.

[36]  COVID-19 Genomics UK (COG-UK) Consortium Report Number 6 , 2020 .

[37]  Yuelong Shu,et al.  GISAID: Global initiative on sharing all influenza data – from vision to reality , 2017, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[38]  S. Lange,et al.  Adjusting for multiple testing--when and how? , 2001, Journal of clinical epidemiology.